Switch theme
Sign up to access all valuation multiples
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
2009
30
Last FY Revenue n/a
LTM EBITDA -$54.8M
$485M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regulus Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$54.8M.
In the most recent fiscal year, Regulus Therapeutics achieved revenue of n/a and an EBITDA of -$45.9M.
Regulus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regulus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$54.8M | XXX | -$45.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$54.4M | XXX | -$50.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$51.6M | XXX | -$46.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Regulus Therapeutics's stock price is $8.
Regulus Therapeutics has current market cap of $549M, and EV of $485M.
See Regulus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $485M | $549M | XXX | XXX | XXX | XXX | $-0.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Regulus Therapeutics has market cap of $549M and EV of $485M.
Regulus Therapeutics's trades at n/a EV/Revenue multiple, and -10.6x EV/EBITDA.
Equity research analysts estimate Regulus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Regulus Therapeutics has a P/E ratio of -10.6x.
See valuation multiples for Regulus Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $549M | XXX | $549M | XXX | XXX | XXX |
| EV (current) | $485M | XXX | $485M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -8.9x | XXX | -10.6x | XXX | XXX | XXX |
| EV/EBIT | -8.9x | XXX | -9.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.6x | XXX | -11.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRegulus Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Regulus Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Regulus Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Regulus Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regulus Therapeutics acquired XXX companies to date.
Last acquisition by Regulus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Regulus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Regulus Therapeutics founded? | Regulus Therapeutics was founded in 2009. |
| Where is Regulus Therapeutics headquartered? | Regulus Therapeutics is headquartered in United States of America. |
| How many employees does Regulus Therapeutics have? | As of today, Regulus Therapeutics has 30 employees. |
| Who is the CEO of Regulus Therapeutics? | Regulus Therapeutics's CEO is Mr. Joseph P. Hagan. |
| Is Regulus Therapeutics publicy listed? | Yes, Regulus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Regulus Therapeutics? | Regulus Therapeutics trades under RGLS ticker. |
| When did Regulus Therapeutics go public? | Regulus Therapeutics went public in 2012. |
| Who are competitors of Regulus Therapeutics? | Similar companies to Regulus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regulus Therapeutics? | Regulus Therapeutics's current market cap is $549M |
| Is Regulus Therapeutics profitable? | Yes, Regulus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Regulus Therapeutics? | Regulus Therapeutics's last 12 months EBITDA is -$54.8M. |
| What is the current EV/EBITDA multiple of Regulus Therapeutics? | Current EBITDA multiple of Regulus Therapeutics is -8.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
